Johnson & Johnson starts trial of COVID-19 vaccine after producing immune response in primates – MarketWatch

Johnson & & Johnson
JNJ, -0.03%.
stated Thursday that its lead vaccine candidate secured against infection with SARS-CoV-2, the infection that triggers COVID-19, in pre-clinical studies. The vaccine provided a robust immune reaction as demonstrated by “reducing the effects of antibodies,” effectively preventing subsequent infection and supplying near-complete or complete defense in the lungs from the virus in non-human primates, the business stated. Based upon the strength of the information, a Phase 1/2a first-in-human medical trial of the vaccine prospect, Ad26.COV2.S, in healthy volunteers, has now begun in the United States and Belgium, the company said. Conversations are underway with partners with the goal to start an essential Phase 3 clinical trial of the single vaccine dosage versus placebo in September, pending the interim information of the Phase 1 and 2 trials and approval of regulators, Johnson & & Johnson stated.

Leave a Reply

Your email address will not be published. Required fields are marked *